Close

Genentech (RHHBY) Receives FDA Priority Review for Lucentis as mCNV Treatment

October 11, 2016 6:17 AM EDT Send to a Friend
Genentech, a member of the Roche Group (OTC: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login